InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate
InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.
How this was made
The 30-second read
Why it matters
The earnings miss and recall charge increase short‑term risk, but the modest EPS beat and announced $9 M annual cost‑saving plan provide a slight upside cushion.
Market read
Earnings release is the primary catalyst for NSPR; no broader macro or sector move.
What to watch
Potential FDA decisions later in 2026 could materially improve outlook if approvals are granted.
Background
InspireMD (Nasdaq: NSPR) is a micro‑cap medical‑device company focused on carotid artery stents, currently facing a voluntary recall of its CGuard Prime 135 cm system.
Ticker impact
InspireMD reported Q2 2026 results with revenue miss and a narrow loss per share beat, plus a recall impact and cost‑saving actions.
Potential further short pressure; price may test lower support around $0.85‑$0.90.
Revenue fell short of estimates and a $734k recall charge hurt margins, while EPS beat is modest and no guidance was given.
Market effects
Highlights ongoing regulatory and recall risks for carotid‑stent manufacturers.
US‑focused recall may weigh on other US med‑device stocks.
Limited; primarily affects micro‑cap investors and niche med‑device sector.
Counterpoint
Cost‑saving actions and a loss‑per‑share beat could support a bounce if cash runway remains sufficient.
Key entities
- ExecutiveMarvin Slosman
CEO of InspireMD, discussed regulatory progress and cost‑saving measures.
